share_log

CSPC Pharmaceutical Group Limited's (HKG:1093) Largest Shareholders Are Individual Investors With 39% Ownership, Institutions Own 31%

CSPC Pharmaceutical Group Limited's (HKG:1093) Largest Shareholders Are Individual Investors With 39% Ownership, Institutions Own 31%

石藥集團有限公司(HKG: 1093)的最大股東是個人投資者,擁有39%的所有權,機構擁有31%
Simply Wall St ·  05/06 18:41

Key Insights

關鍵見解

  • The considerable ownership by individual investors in CSPC Pharmaceutical Group indicates that they collectively have a greater say in management and business strategy
  • A total of 10 investors have a majority stake in the company with 50% ownership
  • Insider ownership in CSPC Pharmaceutical Group is 24%
  • 個人投資者對CSPC製藥集團的大量所有權表明,他們在管理和業務戰略中集體擁有更大的發言權
  • 共有10名投資者持有該公司的多數股權,所有權爲50%
  • CSPC製藥集團的內部所有權爲24%

Every investor in CSPC Pharmaceutical Group Limited (HKG:1093) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 39% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

石藥集團有限公司(HKG: 1093)的每位投資者都應了解最強大的股東群體。我們可以看到,個人投資者擁有公司的大部分股份,所有權爲39%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

And institutions on the other hand have a 31% ownership in the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders.

另一方面,機構擁有該公司31%的所有權。內部人士通常擁有很大一部分年輕、規模較小的公司,而大公司則往往將機構作爲股東。

In the chart below, we zoom in on the different ownership groups of CSPC Pharmaceutical Group.

在下圖中,我們放大了CSPC製藥集團的不同所有權群體。

ownership-breakdown
SEHK:1093 Ownership Breakdown May 6th 2024
SEHK: 1093 所有權明細 2024 年 5 月 6 日

What Does The Institutional Ownership Tell Us About CSPC Pharmaceutical Group?

關於CSPC製藥集團,機構所有權告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

As you can see, institutional investors have a fair amount of stake in CSPC Pharmaceutical Group. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at CSPC Pharmaceutical Group's earnings history below. Of course, the future is what really matters.

如您所見,機構投資者持有CSPC製藥集團的大量股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。如果多家機構同時改變對股票的看法,你可能會看到股價快速下跌。因此,值得在下面查看CSPC製藥集團的收益記錄。當然,未來才是真正重要的。

earnings-and-revenue-growth
SEHK:1093 Earnings and Revenue Growth May 6th 2024
SEHK: 1093 收益及收入增長 2024 年 5 月 6 日

We note that hedge funds don't have a meaningful investment in CSPC Pharmaceutical Group. Our data suggests that Dongchen Cai, who is also the company's Top Key Executive, holds the most number of shares at 24%. When an insider holds a sizeable amount of a company's stock, investors consider it as a positive sign because it suggests that insiders are willing to have their wealth tied up in the future of the company. In comparison, the second and third largest shareholders hold about 6.3% and 6.2% of the stock.

我們注意到,對沖基金沒有對CSPC製藥集團進行有意義的投資。我們的數據顯示,同時也是公司最高主要高管的蔡東晨持股最多,爲24%。當內部人士持有公司大量股票時,投資者認爲這是一個積極的信號,因爲這表明內部人士願意將自己的財富綁定在公司的未來中。相比之下,第二和第三大股東持有約6.3%和6.2%的股份。

On further inspection, we found that more than half the company's shares are owned by the top 10 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

經過進一步檢查,我們發現公司一半以上的股份由前十名股東持有,這表明較大股東的利益在一定程度上被較小的股東所平衡。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。有很多分析師在報道該股,因此可能也值得一看他們的預測。

Insider Ownership Of CSPC Pharmaceutical Group

CSPC製藥集團的內部所有權

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間確實有所不同。我們的數據反映了個人內部人士,至少涵蓋了董事會成員。公司管理層經營業務,但首席執行官將對董事會負責,即使他或她是董事會成員。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

當內部所有權表明領導層像公司的真正所有者一樣思考時,內部所有權是積極的。但是,高度的內部所有權也可以賦予公司內部的一小部分人巨大的權力。在某些情況下,這可能是負面的。

Our information suggests that insiders maintain a significant holding in CSPC Pharmaceutical Group Limited. It is very interesting to see that insiders have a meaningful HK$19b stake in this HK$80b business. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人士持有CSPC製藥集團有限公司的大量股份。有趣的是,內部人士在這項800億港元的業務中擁有190億港元的大量股份。大多數人會說,這表明了與股東的良好一致性,尤其是在如此規模的公司中。你可以點擊這裏查看這些內部人士是否在買入或賣出。

General Public Ownership

一般公有制

With a 39% ownership, the general public, mostly comprising of individual investors, have some degree of sway over CSPC Pharmaceutical Group. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

CSPC製藥集團擁有39%的所有權,主要由個人投資者組成的公衆對CSPC製藥集團有一定程度的影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Private Company Ownership

私人公司所有權

We can see that Private Companies own 6.4%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,私人公司擁有已發行股份的6.4%。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 1 warning sign for CSPC Pharmaceutical Group that you should be aware of.

儘管值得考慮擁有公司的不同群體,但還有其他因素更爲重要。例如,我們已經確定了CSPC製藥集團的一個警告信號,你應該注意這一點。

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果你想了解分析師對未來增長的預測,千萬不要錯過這份關於分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論